Johnston, Iowa, USA (September 4, 2013) — Biova® LLC, the world leader in water soluble egg membrane ingredients for joint and skin health applications, has finalized an agreement with Connell Brothers to be the distributor of Biova’s ingredient portfolio in select Asia-Pacific countries, as well as India.
“Connell Brothers’ supply chain management capabilities are unmatched,” said Allen Levine, international and natural accounts with Biova. “We love their market reach, technical capabilities and track record of success.”
Johnston, Iowa, USA (May 14, 2013) — Biova® LLC, the leading supplier of water soluble egg membrane, has finalized an agreement with Maypro Industries® to be the preferred distributor of Biova’s ingredient portfolio in Japan and Taiwan.
“Maypro is a proven industry leader,” said Matt Stegenga, Biova’s director of sales and marketing. “They recognize that BiovaFlex® and BiovaDerm® will fill important niches in their impressive portfolio of quality proprietary branded ingredients. Joint health and skin health products are priorities for the consumer. Like us, Maypro believes in innovation—we love their experience and track record of success.”
Johnston, Iowa, USA (March 18, 2013) — Biova® has retained Ford Levine Sales Group for natural markets and international sales development. Biova is the market leader for water-soluble egg membrane ingredients.
“Increased market interest in our water soluble branded ingredients and expanded global opportunities are the driving forces behind this agreement,” said Matt Stegenga, Biova director of sales and marketing. “Ford Levine are talented professionals with a proven track record of success with natural, international account development. We’re excited they’re now part of our team.”
Johnston, Iowa, USA (February 28, 2013) — Biova® LLC, developer of patented Hydro5™ technology for water-soluble egg membrane, has increased the standardized protein profile of its BiovaFlex® ingredient to what it believes is a market-leading 88 percent.
“The science indicates bioactivity is tied to the natural, non-denatured egg membrane matrix,” said Matt Stegenga, Biova director of marketing. “The primary composition of this matrix is a natural ratio of complex proteins including glycosaminoglycans, collagen, elastin, desmosine, isodesmosine and transforming growth factor. So yes, hitting uniform 88 percent protein across all BiovaFlex production is significant for us because it’s important for our customers’ products.”
Carthage, Missouri, and Johnston, Iowa, USA; October 30, 2012 — ESM Technologies, LLC (“ESM”) and Biova, LLC (“Biova”) have resolved their differences and have agreed that each can continue to market and sell their respective current products. Biova does not believe U.S. Patent No. 6,946,551 (“the ‘551 Patent”) was properly construed, is valid or infringed, but, to forego the need for further litigation or an appeal and to resolve the matter fully between the parties, Biova agrees that the claims as construed by the District Court would have covered Biova’s process, and the ‘551 Patent is valid and enforceable.